The benefits of using Synchrony™ Respiratory Tracking System ͑RTS͒ in conjunction with the CyberKnife robotic treatment device to treat a "breathing tumor" in an anthropomorphic, tissueequivalent, thoracic phantom have been investigated. The following have been studied: ͑a͒ Synchrony's ability to allow the CyberKnife to deliver accurately a planned dose distribution to the free-breathing phantom and ͑b͒ the dosimetric implications when irregularities in the breathing cycle and phase differences between internal ͑tumor͒ and external ͑chest͒ motion exist in the course of one treatment fraction. The breathing phantom PULMONE ͑phantom used in lung motion experiments͒ has been used, which can imitate regular or irregular breathing patterns. The breathing traces from two patients with lung cancer have been selected as input. Both traces were irregular in amplitude, frequency, and base line. Patient B demonstrated a phase difference between internal and external motion, whereas patient A did not. The experiment was divided into three stages: In stage I-static, the treatment was delivered to the static phantom. In stage II-motion, the phantom was set to breathe, following the breathing trace of each of the two patients. Synchrony™ was switched off, so no motion compensation was made. In stage III-compensation, the phantom was set to breathe and Synchrony™ was switched on. A linear correspondence model was chosen to allow for phase differences between internal and external motion. Gafchromic EBT film was inserted in the phantom tumor to measure dose. To eradicate small errors in film alignment during readout, a gamma comparison with pass criteria of 3%/3 mm was selected. For a more quantitative approach, the percentage of pixels in each gamma map that exceeded the value of 1 ͑P 1 ͒ was also used. For both breathing signals, the dose blurring caused by the respiratory motion of the tumor in stage II was degraded considerably compared with stage I ͑P 1 =15% for patient A and 8% for patient B͒. The motion compensation via the linear correspondence model was sufficient to provide a dose distribution that satisfied the set gamma criteria ͑P 1 =3% for patient A and 2% for patient B͒. Synchrony™ RTS has been found satisfactory in recovering the initial detail in dose distribution, for realistic breathing signals, even in the case where a phase delay between internal tumor motion and external chest displacement exists. For the signals applied here, a linear correspondence model provided an acceptable degree of motion compensation.
I. INTRODUCTION
Lung cancer is the most common cancer in the world with 1.3 million new cases diagnosed every year. It is also the most common fatal malignancy in the developed world, with over 33 500 deaths per year in the U.K. ͑Cancer Research U.K., CancerStats 2006͒. 27 Survival rates remain poor with 25% of patients being alive 1 year after diagnosis. This falls to 7% at 5 years. If survival figures are to improve for pa-tients undergoing radiation therapy, attention should be focused around the issue of accounting for the presence of respiratory motion. This motion during treatment limits the accuracy of irradiating the tumor. At the same time, healthy tissues in the vicinity may receive doses near their tolerance level. Overall this can lead to poor survival following radiotherapy and/or an increase in side effects following treatment. Furthermore, with respiratory motion as a limiting factor, 1,2 it has not been possible to increase the dose to the tumor to levels that have been anticipated to achieve a higher probability of tumor control. 3 In order to correct for the tumor's motion, it is necessary at first to measure it. 4 Lung tumors do not move in a reproducible way, neither during the course of one treatment nor on different days. [5] [6] [7] [8] As a result, planning an entire treatment upon breathing data that were acquired on separate days even for the same patient, may not be a satisfactory solution. To provide a viable solution that can be incorporated in the treatment room, repeated x-ray fluoroscopic guidance is being used in some systems. 9 However, this has been found to increase the dose to the patient. 10 Alternatively, observing the motion of a surrogate such as the external surface of the chest has been proposed by several workers. Nevertheless, the relationship between internal and external motion may also change with time and the external motion alone is not a good indicator of what is happening internally. [11] [12] [13] Therefore, an ideal system would be a hybrid of the two, combining both sets of information to generate a more robust prediction model.
This article aims to examine the degree to which the CyberKnife robotic treatment device ͑Accuray, Inc., Sunnyvale, CA͒ in combination with the Synchrony™ Respiratory Tracking System ͑RTS͒ can provide a practical solution to the motion problem in lung radiotherapy. The CyberKnife has a 6 MV linear accelerator mounted on a robotic arm that gives it six degrees of freedom of motion.
14 Hence, it has the potential to follow moving targets in real time, while delivering photon beams of various sizes. Synchrony™ RTS linked to the CyberKnife, has been designed to actively compensate for breathing motion while a patient is breathing normally. Synchrony™ uses two detector systems: ͑a͒ an orthogonal pair of kilovolt ͑kV͒ fluoroscopic imagers measure the positions of radio-opaque markers implanted in or near the tumor and ͑b͒ a stereo camera system measures the position of one or more infrared emitting markers placed on the chest or abdomen. During treatment the fluoroscopic imagers are saturated by the megavoltage beam, so Synchrony™ uses the position of the external markers as a surrogate for the ͑internal͒ motion of the tumor. Prior to treatment, Synchrony™ simultaneously measures the tumor and external motion for several breathing cycles. It uses these measurements to build a "correspondence model" between the internal and external motion, given that these are, in general, both well correlated and cyclical for the duration of time between two consecutive samples. During treatment, Synchrony™ measures the external motion and uses the correspondence model to estimate the tumor position, instructing the robotic arm to move accordingly. Treatment is briefly and periodically interrupted to allow the fluoroscopic system to measure the actual tumor position and, hence, ensure that the correspondence model is still valid. If a discrepancy is found, the treatment is interrupted to rebuild the model. 15 The ability of Synchrony™ to monitor external motion and build a correspondence model and update it regularly is being examined here. The dosimetric impact of its application has not been looked into before. Via a series of experiments using a breathing phantom with the CyberKnife, we investigated the following: ͑a͒ Synchrony's ability to allow the CyberKnife to deliver the planned dose distribution to the free-breathing phantom. The accuracy of doing so was quantified. ͑b͒ The dosimetric implications following the use of a linear correspondence model, in particular when irregularities in the breathing cycle and phase differences between internal ͑tumor͒ and external ͑chest͒ motion exist and additionally change in the course of one treatment fraction.
The breathing phantom constructed is anthropomorphic in shape and has the ability to imitate any regular or irregular breathing pattern. Moreover, it can be used for multiplanar dosimetry inside the tumor and lung mass.
II. METHOD

II.A. Phantom properties
The breathing phantom ͓phantom used in lung motion experiments ͑PULMONE͔͒ has been presented elsewhere; 16 it is shaped like a human thorax, made of Perspex ͓poly͑meth-ylmethacrylate͔͒ and contains two accordion-type collapsible bottles that represent the lungs. These are surrounded by water to replicate the chest mass and filled in with dampened sponges to simulate the lung mass and produce a similar computed tomography ͑CT͒ number to the human lung. One of the lungs can host a cylindrical tumor, which is linked to and can be moved by a high-precision linear platform. The link to the lung then mimics diaphragmatic motion and the tumor itself can move in all three dimensions ͑movie 1͒. 28 However, a number of modifications have been made to the previous design, not only to improve the phantom's usability and its practicability for lung radiotherapy experiments but also to satisfy the recommendations of AAPM TG76. 17 Both ends of the Perspex thorax construction have been sealed, so that PULMONE can lie supine on the treatment couch ͑Fig. 1͒. A reservoir has been added to receive the water displaced by the lungs as the phantom breathes. The tumor can be loaded from the superior end of the lung and is secured in place by a long screw that passes through the center of the link rod to the platform. It is then surrounded by dampened sponges as described before. The tumor has been changed to facilitate measurement of dose in the normal lung tissue as well: a cylindrical layer of cork encompasses the Perspex tumor and the dosimetric film can now extend in the lung area, outside the CTV boundaries ͑Fig. 2͒. There are two film inserts, F1 and F2, that can be orientated to coincide with the major direction of motion. Four ͑1 mmϫ 4 mm͒ x-ray opaque, rod-shaped fiducial markers have been "implanted" in the cork near the tumor, such that their position remains unchanged between planning and delivery. The markers allow the x-ray component of Synchrony™ to measure the tumor position. They have been placed in a way that they can be visible from the two orthogonal panel x-ray detectors.
In order to simulate external motion, a plastic rod has been added above the anterior surface of the phantom. The rod is spring-loaded onto an eccentric wheel that is driven by an independent stepper motor, allowing the anterior-posterior motion of the rod to be controlled and synchronized to the tumor motion. The Synchrony™ infrared markers are attached to the rod. As with the previous design, PULMONE can breathe to any regular or irregular trace and on this occasion, the latter has been selected as the method of choice ͑movie 2͒. 28 
II.B. Selection of breathing traces
Breathing traces from two patients with lung cancer have been selected as input ͑Fig. 3͒. These synchronized recordings of both internal tumor motion and external abdominal motion of patients treated with real-time-tumor-tracking radiotherapy as published by Berbeco et al. 18 were obtained at the Radiation Oncology clinic at the Nippon Telegraph and Telephone Corporation Hospital in Sapporo, Japan, and were acquired with a Mitsubishi RTRT system. 19 In this setting, the internal motion was acquired by monitoring in real time with a dual-panel fluoroscopic system the motion of two to four 1.5 mm diameter gold spheres implanted in or near the tumor. External motion was monitored simultaneously by the AZ-733V external respiratory gating system ͑Anzai Medical, Tokyo, Japan͒, which uses a laser to monitor the movement of the patient's abdominal surface. The signal from the surface monitor was matched with the signal from the fluoroscopic unit so that the log files contain the three-dimensional marker positions and the external surface position at every time point. The rate of data acquisition for this system is 30 frames/s.
The two patient traces were selected on grounds of ͑ir-͒regularity and phase differences. Both patients showed irregularities in amplitude, frequency, and base line in their breathing patterns as tends to happen often in real life situations. [5] [6] [7] [8] Patient B demonstrated a phase difference between internal and external motion, a phenomenon that has often been referred to as "hysteresis." Patient A did not show that effect and was chosen on purpose in order to contrast to patient B's case and to study separately Synchrony's ability to track such signals. As the acquired recordings were of 2 min maximum duration, they were cut and looped in a way that the transition was smooth and a long breathing signal could be achieved. Furthermore, all signals were smoothed by averaging each point with its seven nearest neighbors to prevent unnecessary jumps and resampled at 32 ms intervals for compatibility with the motion platform software. It was ensured that existing phase differences were preserved.
II.C. Treatment-planning stage
A static CT image set of the phantom was used for treatment planning, with the phantom considered to be at the maximum exhale position of its breathing cycle. The CT slices were taken at 1.25 mm intervals with a four-slice GE scanner in helical mode.
The CyberKnife system uses many noncoplanar and nonisocentric beam directions to produce highly conformal treatment plans with a cone beam ͑0.5-6 cm diameter͒. For this study one collimator was used with an aperture of 2 cm in diameter. With CYRIS™ Multiplan™ treatment-planning system ͑Accuray, Inc., Sunnyvale, CA͒, inverse planning was used to obtain a 6 MV nonisocentric treatment around a virtual target volume. The plan was designed such that both a It is held by a rod that is attached to the moving platform. The "tumor" is tightly surrounded by cork to imitate lung tissue. Two thin slots along the cranio-caudal direction can hold Gafchromic film for dose measurements. Three of the four radio-opaque fiducial markers can be seen embedded in the surface of the cork.
high dose ͑ϳ5 Gy͒ region and a low dose region ͑ϳ2 Gy͒ with sufficient dose gradients were present at the planes of the inserted films. Effects of motion are sooner visible in a dose distribution with high dose gradients than in a smoother, more realistic plan. Forty-five beams were initially planned, but 15 of those were deleted for reasons explained in the following section. This is less than for a normal treatment with a noncylindrical shape of the tumor. But the directions of the beams were representative for a normal treatment.
With a dose rate of 400 MU/min, the treatment duration was approximately 15 min.
II.D. Treatment delivery
The experiments described in this work were carried out at the Erasmus MC-Daniel den Hoed Cancer Centre in Rotterdam, the Netherlands. All experiments were carried out on the same day.
The phantom was setup supine on the treatment couch, with the diaphragmatic motion being along its long ͑horizon-tal͒ axis, and the driving platform being at its inferior end. The tumor was placed in its left lung. A "dry-run" with the radiation switched off was initially performed, to ensure there were no collisions of the robotic arm with the phantom and platform. This demonstrated some prohibiting directions, which would have lead to a collision of the robotic arm with the motion platform and as a result it was decided to discard a whole set of treatment nodes from the initial plan ͑This occurred because the motion platform's dimensions exceeded the patient safety zone by a few centimeters. The platform had not been CT scanned with the phantom and had therefore not been used in treatment-planning either. Clearly, this is not expected to occur in real life situations.͒ Consequently, target dose homogeneity was not achieved and large dose gradients were present within the target volume ͑as described in Sec. II C͒. This, however, was accepted on the grounds that it could provide an insight into the effect of motion in areas with dose inhomogeneities.
The experiment was divided into three stages:
• In stage I-static, a set of kV x rays was taken for initial positioning. These were acquired by the two amorphous silicon panel x-ray detectors, which are situated opposite two ceiling-mounted x-ray tubes. The lungimplanted fiducials were traced in the images and matched to the planning-stage digitally reconstructed radiographs. The couch was adjusted by translation and tilting, to minimize set-up error. The treatment plan was delivered to the static phantom. This stage was used as a reference against which the other two stages could be compared. It also replaced the planning stage, given the above-mentioned deletion of delivery nodes, such that a similar measure of comparison would be used throughout the experiment. Stage I-static was repeated twice and the difference between film readouts did not exceed the error of film measurement.
• In stage II-motion, the phantom was set to breathe, following the breathing trace of each of the two patients. However, Synchrony™ was switched off and no motion compensation was made. This situation would not have been chosen in a real-case scenario but was used to demonstrate the effects of breathing motion when it is not taken in consideration. X rays were taken for localization and matching but were not used to make any corrections other than for the initial setup.
• In stage III-compensation, the phantom was set to breathe and Synchrony™ was switched on. A linear correspondence model 20 was chosen for the purposes of this experiment. Synchrony™ RTS had to rebuild its model a few times during treatment, for both of the breathing patterns. The tolerance had been set to 3 mm.
II.E. Film analysis
Gafchromic EBT film was inserted in the tumor for dosimetry. Conventional radiotherapy film would have required careful packaging and manual processing if cut to fit the slits in the tumor. Gafchromic EBT film, on the other hand, does not need developing, may be cut easily to any desired shape, and most importantly, has a consistent response to dose at the dose range of interest to this experiment.
Calibration films were taken at several MU settings with a 6 MV linear accelerator beam, operated at 400 MU/min because the absence of a flattening filter in the CyberKnife profile prohibits the acquisition of calibration films in its beam. The linac fields used were 5 cmϫ 5 cm at 100 cm SSD, 5 cm deep in solid water, and covered the range of doses irradiating the target.
The dose information on the Gafchromic films was digitized using a flatbed scanner ͑Epson Expression 1680Pro, Epson, UK͒, which has been reported to be an excellent tool for accurate two-dimensional dosimetry with this type of film. 21 The films were given 24 h postirradiation to "self-develop." 22 They were scanned at the same region of the scanner's surface and with the same orientation as the calibration films, as recommended by the film manufacturers ͑International Specialty Products, New Jersey, USA͒. The scanner was set to produce 48-bit RGB ͑red-green-blue͒ images of 100 dots per inch resolution and to repeat each pixel measurement eight times to further increase the quality of the readout. The conversion to dose was based on the calibration curve, which covered the dose range ͑0.5-8͒ Gy and used in combination the red and green color channel readings of the RGB image. 23 A program developed in-house converted the data to ASCII files, 24 which were then imported to OmniPro ͑OmniPro-I'mRT, Scanditronix-Wellhöfer, Schwarzenbruck, Germany͒. Film registration was straightforward, given the asymmetrical shape of the films. The uncertainty of the Gafchromic film measurement was considered to be within 3% as found by departmental quality-assurance reproducibility tests ͑a film plus scanner technique͒.
III. RESULTS
Figures 4 and 5 summarize the findings for patient A, whose motion effects were more pronounced, as measured by the films placed in the F1 and F2 inserts of the tumor, respectively. These films were either static or moving along the major axis of motion ͑the cranio-caudal͒ and are therefore anticipated to demonstrate the full extent of the impact of breathing motion. Dose distributions as read out from the inserted films are shown in the first column. The scale is in absolute dose in cGy. ͑a͒, ͑b͒, and ͑c͒ correspond to stages I-static, II-motion, and III-compensation of the experiment. The subsequent columns contain comparative summaries for stages I-static versus II-motion and I-static versus IIIcompensation accordingly. The top row shows isodose distributions of the registered films. A more representative method of demonstrating differences in areas of such high gradients as the ones presented in this context is by using a gamma comparison. Small errors in film alignment on the flatbed scanner might cause misleading differences, too, so the pass criteria for the gamma test were set to 3% differences in dose, in a 3 mm search distance. Normally, a higher degree of precision would be anticipated in a radiosurgery setting. However, this figure was limited by the accuracy of film readout, hence, the choice of 3% difference in dose. Furthermore, the process of placing accurately separate films on exactly the same area of the flatbed scanner was deemed to entail a 3 mm error ͑this is higher than the spatial accuracy of the EBT film͒. The bottom row illustrates the gamma maps of the dose map comparisons. The images are sufficient to qualitatively express the effect of motion blurring and the degree of correction that Synchrony™ has achieved. For a more quantitative approach, Table I tabulates the percentage of pixels in the gamma maps that has exceeded the value of 1 ͑P 1 ͒. These percentages have been considered as a representative overall measure of the transition between the different stages. Table I contains data for both patients and all transitions.
IV. DISCUSSION
For both breathing signals and both films, the dose blurring caused by the respiratory motion of the tumor in stage II-motion, degraded considerably the dose distribution of stage I-static. This was more pronounced for the films that were placed in slot F2, where they received a wider range of doses. It was also more pronounced for the breathing signal of patient A, who demonstrated a more irregular breathing motion. The distribution of the rejected areas in the gamma map did not relate to areas of either high or low dose gradient in the static delivery. When looking at the comparison between stages I-static and III-compensation, the advantage of tracking with Synchrony™ is clear; for all films, the motion compensation is achieved. The maximum observed mismatch that did not satisfy the set gamma criteria, did not exceed 3% ͑Table I͒.
Having established the degree of dose recovery with the use of Synchrony's linear correspondence model, it is interesting to investigate whether this is more beneficial for a breathing signal demonstrating internal-versus-external hys- FIG. 4 . ͑a͒ Dose distribution resulting from the delivery of the planned CyberKnife treatment to the films placed in slot F1 while the phantom was static. ͑Stage I-static͒ ͑b͒ Dose distribution for the same treatment delivery, but with the phantom breathing according to the breathing trace of patient A. ͑Stage II-motion͒ ͑c͒ Same as in ͑b͒, but with Synchrony™ RTS switched on, and compensating for the breathing motion using the linear correspondence model ͑Stage III-compensation͒. The thermal color scale relates to ͑a͒, ͑b͒, and ͑c͒ and gives absolute dose in cGy. ͑d͒ is an isodose distribution comparison between ͑a͒ and ͑b͒, with the solid lines corresponding to stage I-static and the dotted lines to stage II-motion. The color coding is summarized in the inset next to it, also in cGy. ͑e͒ is the result of the gamma map comparison of the same stages with acceptance criteria of 3%, 3 mm. ͑f͒ is an isodose distribution comparison between ͑a͒ and ͑c͒, with the solid lines corresponding to stage I-static and the dotted lines to stage III-compensation. The same color coding applies as in ͑d͒. ͑g͒ is the gamma map comparison of the same stages with acceptance criteria of 3%, 3 mm. The gamma values have been color coded as shown in the inset between ͑e͒ and ͑g͒. All moving films were moving in the major plane of motion. The arrows show film orientations.
teresis as opposed to another that does not. Looking again in Table I , it can be deduced that Synchrony™ coped equally well with both types of breathing traces, regardless of the amount of blurring that was caused in its absence. The linear correspondence model was sufficient to provide a dose distribution that satisfied the set gamma comparison criteria between the static and the motion-compensated phase. In a previous publication, 15 more sophisticated correspondence models were found to reduce further the positional error in some situations. However, in terms of dose, and for the patient signals studied here, the linear correspondence model is deemed to provide a satisfactory level of motion compensation.
It should be noted that this experiment has assumed a rigid body motion and as such no "differential" or "elastic" motion arises. 25 However, the motion of the tumor was varying the density of the lung phantom and Synchrony™ could not be expected to solve for that. However, it has been shown that this is a small effect. 26 Moreover, Synchrony's capabilities have not been studied to their full extent, as this phantom's tumor cannot pitch, yaw, and roll. This would have additionally required breathing traces that would contain such information, something that was not acquired by the RTRT system.
Several kilovoltage x-ray images were acquired during each stage of delivery. Nevertheless, it is not expected that their use affected the dose received by the EBT films, especially as the sensitivity of EBT films to kV energies is small. Furthermore, the films were exposed to the same number of x radiographs at each stage, so that any potential contribution would have increased all dose readings by the same amount. The dose delivered by this experiment was scaled down so that the total dose was within the 10 Gy limit for EBT film. Consequently, the dwell time at each node during the experiment was shorter than that for a patient's treatment. This may lead to the experiment giving a ͑slightly?͒ optimistic measure of Synchrony's ability to track motion, yet Synchrony™ still had to position the linac to the correct position at the start of each node.
However, the advantages of the CyberKnife treatment in combination with Synchrony™ RTS over conventional linear-accelerator radiotherapy remain strong: this type of treatment has a 100% duty cycle of treatment, leading to fuller resource use ͑compared to, for example, gating or breath hold treatments͒. In addition, there is no need for any intervention to the patient's breathing, as they are left to breathe normally and let the correspondence model take into account irregularities in their breathing cycle. The model can be updated frequently enough to keep a balance between the time needed for a breathing signal to drift or change and the additional dose from x rays necessary to locate the tumor. Hence, day-to-day and even cycle-to-cycle variations can be compensated for and of course, it is all patient-specific. Furthermore, the acquired images are used to monitor and correct any set-up errors as required by the demands of imageguided radiotherapy.
On the other hand, predict-ahead models are built with a small delay from the time of external marker signal acquisition. No matter how fast this happens, there will always be brief occasions when the patient's chest motion does not match the prediction. Additionally, some intervention is required for the system to work: It is necessary that gold markers are implanted in or near the tumor in order to gain in accuracy of tumor localization. Implanted fiducial markers of course, might not be either a true representation of the tumor motion, as they are not part of the tumor itself, they have just been implanted and act as a surrogate. Finally, the CyberKnife is not routinely accessible by many radiotherapy centers, so despite its advantages it is not an available treatment option for many lung cancer patients.
V. CONCLUSIONS
This study has looked at the degree of degradation that can occur when delivering a CyberKnife treatment to a breathing tumor of an anthropomorphic, tissue-equivalent thoracic phantom. The benefits of using the Synchrony™ RTS System in conjunction with the treatment have been identified and demonstrated. The tracking solution has been found satisfactory in recovering the initial detail in dose distribution, for realistic, irregular breathing signals, even in the case where there is a phase delay between internal tumor motion and external chest displacement. For the particular signals applied here, a linear correspondence model provided an acceptable degree of motion compensation. As the applied breathing traces were randomly chosen, we believe that Synchrony™ should have the potential of tracking any other irregular trace with a similar degree of achievement.
